IGM BIOSCIENCES INC (IGMS)
US4495851085 - Common Stock
IGM Biosciences Becomes Oversold (IGMS)
IGM Biosciences is Now Oversold (IGMS)
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – ...
IGM Biosciences to Present at Three Upcoming Investor Conferences
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
The company is making a complete shift out of oncology and into autoimmune diseases.
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis...
Notable Tuesday Option Activity: GEO, CHDN, IGMS
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024
IGMS stock results show that IGM Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
IGMS Stock Earnings: IGM Biosciences Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IGM Biosciences (NASDAQ:IGMS) just reported results for the second quarter of 2...
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose...
Notable Two Hundred Day Moving Average Cross - IGMS
Commit To Purchase IGM Biosciences At $10, Earn 30.4% Annualized Using Options
IGM Biosciences Breaks Above 200-Day Moving Average - Bullish for IGMS
IGM Biosciences is Now Oversold (IGMS)
IGM Biosciences to Present at the Jefferies Healthcare Conference
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...